107 related articles for article (PubMed ID: 22771314)
41. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
[TBL] [Abstract][Full Text] [Related]
42. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
[TBL] [Abstract][Full Text] [Related]
43. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Riely GJ
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Gil S; Goetgheluck J; Paci A; Broutin S; Friard S; Couderc LJ; Ayoubi JM; Picone O; Tcherakian C
Lung Cancer; 2014 Sep; 85(3):481-4. PubMed ID: 24997732
[TBL] [Abstract][Full Text] [Related]
45. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
47. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
Azuma K; Okamoto I; Kawahara A; Taira T; Nakashima K; Hattori S; Kinoshita T; Takeda M; Nakagawa K; Takamori S; Kuwano M; Ono M; Kage M
J Thorac Oncol; 2012 Jan; 7(1):122-7. PubMed ID: 21892099
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
49. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
50. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
[TBL] [Abstract][Full Text] [Related]
51. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.
Wu X; Liang W; Hou X; Lin Z; Zhao H; Huang Y; Fang W; Zhao Y; Wu J; Yang Y; Xue C; Hu Z; Zhang J; Zhang J; Ma Y; Zhou T; Qin T; Zhang L
Onco Targets Ther; 2013; 6():1481-91. PubMed ID: 24204163
[TBL] [Abstract][Full Text] [Related]
52. Robust Acute Pancreatitis Identification and Diagnosis: RAPIDx.
Zhu Q; Luo J; Li HP; Ye W; Pan R; Shi KQ; Yang R; Xu H; Li H; Lee LP; Liu F
ACS Nano; 2023 May; 17(9):8564-8574. PubMed ID: 36988967
[TBL] [Abstract][Full Text] [Related]
53. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
Peters S; Stahel RA; Dafni U; Ponce Aix S; Massutí B; Gautschi O; Coate L; López Martín A; van Heemst R; Berghmans T; Meldgaard P; Cobo Dols M; Garde Noguera J; Curioni-Fontecedro A; Rauch D; Mark MT; Cuffe S; Biesma B; van Henten AMJ; Juan Vidal Ó; Palmero Sanchez R; Villa Guzmán JC; Collado Martin R; Peralta S; Insa A; Summers Y; Láng I; Horgan A; Ciardiello F; de Hosson S; Pieterman R; Groen HJM; van den Berg PM; Zielinski CC; Chittazhathu Kurian Kuruvilla Y; Gasca-Ruchti A; Kassapian M; Novello S; Torri V; Tsourti Z; Gregorc V; Smit EF;
J Thorac Oncol; 2017 Apr; 12(4):752-762. PubMed ID: 28017787
[TBL] [Abstract][Full Text] [Related]
54. Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy.
Li Z; Chen J; Xu B; Zhao W; Zha H; Han Y; Shen W; Dong Y; Zhao N; Zhang M; He K; Li Z; Liu X
Clin Proteomics; 2024 May; 21(1):35. PubMed ID: 38764042
[TBL] [Abstract][Full Text] [Related]
55. Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance.
Koc MA; Wiles TA; Weinhold DC; Rightmyer S; Weaver AL; McDowell CT; Roder J; Asmellash S; Pestano GA; Roder H; Georgantas Iii RW
J Mass Spectrom Adv Clin Lab; 2023 Nov; 30():51-60. PubMed ID: 38074293
[TBL] [Abstract][Full Text] [Related]
56. SAA1 identified as a potential prediction biomarker for metastasis of hepatocellular carcinoma
Li G; Shen Q; Xu H; Zhou Y; Li C; Li Y; He M
Front Oncol; 2023; 13():1138995. PubMed ID: 37081987
[TBL] [Abstract][Full Text] [Related]
57. The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer.
Moonmuang S; Tantraworasin A; Orrapin S; Udomruk S; Chewaskulyong B; Pruksakorn D; Chaiyawat P
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902280
[TBL] [Abstract][Full Text] [Related]
58. DIGE Analysis of ProteoMiner™ Fractionated Serum/Plasma Samples.
Murphy S; Dowling P
Methods Mol Biol; 2023; 2596():119-125. PubMed ID: 36378436
[TBL] [Abstract][Full Text] [Related]
59. Eight hub genes as potential biomarkers for breast cancer diagnosis and prognosis: A TCGA-based study.
Liu N; Zhang GD; Bai P; Su L; Tian H; He M
World J Clin Oncol; 2022 Aug; 13(8):675-688. PubMed ID: 36160462
[TBL] [Abstract][Full Text] [Related]
60. Serum Extracellular Vesicle Stratifin Is a Biomarker of Perineural Invasion in Patients With Colorectal Cancer and Predicts Worse Prognosis.
Hou W; Pan M; Xiao Y; Ge W
Front Oncol; 2022; 12():912584. PubMed ID: 35936690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
